Dutch-based Alveron Pharma raises 5M to advance therapy for intracranial haemorrhage - Silicon CanalsAlveron Pharma secured €5M funding to advance OKL-1111, a drug designed to treat intracranial haemorrhage and improve patient outcomes.
Glucose-sensitive insulin with attenuation of hypoglycaemia - NatureThe quest for glucose-responsive insulin seeks to prevent hypoglycaemia while maintaining optimal glucose control.Engineering glucose-responsive properties in insulin itself offers a promising alternative to existing methods for diabetes management.
I'm the Danish scientist who pioneered injectable drugs like Ozempic. Here are my 3 tips for inventing blockbuster products.Lotte Bjerre Knudsen's research was pivotal in transforming short-acting GLP-1 hormones into successful long-acting diabetes treatments like Ozempic.
Glucose-sensitive insulin with attenuation of hypoglycaemia - NatureThe quest for glucose-responsive insulin seeks to prevent hypoglycaemia while maintaining optimal glucose control.Engineering glucose-responsive properties in insulin itself offers a promising alternative to existing methods for diabetes management.
I'm the Danish scientist who pioneered injectable drugs like Ozempic. Here are my 3 tips for inventing blockbuster products.Lotte Bjerre Knudsen's research was pivotal in transforming short-acting GLP-1 hormones into successful long-acting diabetes treatments like Ozempic.
Sanofi CEO Paul Hudson takes inspiration from 'Fight Club' to get his team hooked on AISanofi is integrating AI across its value chain, highlighting its commitment to innovation during a recent hackathon led by CEO Paul Hudson.
What Alicia Boler Davis had to 'unlearn' from Jeff Bezos and Amazon to lead digital pharmacy AltoAlicia Boler Davis transitioned from Amazon to Alto to leverage her skills and impact the antiquated pharmacy industry.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030Eli Lilly's stock has experienced significant growth, indicating strong market confidence and potential for future stock splits.Investors should focus on projected revenue and innovations rather than solely on past performance when evaluating Eli Lilly's future.